tetano
Editor, Senior Moderator
PLoS Pathog
. 2023 Apr 17;19(4):e1011342.
doi: 10.1371/journal.ppat.1011342. Online ahead of print.
4'-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses
Carolin M Lieber[SUP] 1 [/SUP], Megha Aggarwal[SUP] 1 [/SUP], Jeong-Joong Yoon[SUP] 1 [/SUP], Robert M Cox[SUP] 1 [/SUP], Hae-Ji Kang[SUP] 1 [/SUP], Julien Sourimant[SUP] 1 [/SUP], Mart Toots[SUP] 1 [/SUP], Scott K Johnson[SUP] 2 [/SUP], Cheryl A Jones[SUP] 2 [/SUP], Zachary M Sticher[SUP] 3 [/SUP], Alexander A Kolykhalov[SUP] 3 [/SUP], Manohar T Saindane[SUP] 3 [/SUP], Stephen M Tompkins[SUP] 2 [/SUP], Oliver Planz[SUP] 4 [/SUP], George R Painter[SUP] 3 [/SUP], Michael G Natchus[SUP] 3 [/SUP], Kaori Sakamoto[SUP] 5 [/SUP], Richard K Plemper[SUP] 1 [/SUP]
Affiliations
Abstract
Influenza outbreaks are associated with substantial morbidity, mortality and economic burden. Next generation antivirals are needed to treat seasonal infections and prepare against zoonotic spillover of avian influenza viruses with pandemic potential. Having previously identified oral efficacy of the nucleoside analog 4'-Fluorouridine (4'-FlU, EIDD-2749) against SARS-CoV-2 and respiratory syncytial virus (RSV), we explored activity of the compound against seasonal and highly pathogenic influenza (HPAI) viruses in cell culture, human airway epithelium (HAE) models, and/or two animal models, ferrets and mice, that assess IAV transmission and lethal viral pneumonia, respectively. 4'-FlU inhibited a panel of relevant influenza A and B viruses with nanomolar to sub-micromolar potency in HAE cells. In vitro polymerase assays revealed immediate chain termination of IAV polymerase after 4'-FlU incorporation, in contrast to delayed chain termination of SARS-CoV-2 and RSV polymerase. Once-daily oral treatment of ferrets with 2 mg/kg 4'-FlU initiated 12 hours after infection rapidly stopped virus shedding and prevented transmission to untreated sentinels. Treatment of mice infected with a lethal inoculum of pandemic A/CA/07/2009 (H1N1)pdm09 (pdmCa09) with 4'-FlU alleviated pneumonia. Three doses mediated complete survival when treatment was initiated up to 60 hours after infection, indicating a broad time window for effective intervention. Therapeutic oral 4'-FlU ensured survival of animals infected with HPAI A/VN/12/2003 (H5N1) and of immunocompromised mice infected with pdmCa09. Recoverees were protected against homologous reinfection. This study defines the mechanistic foundation for high sensitivity of influenza viruses to 4'-FlU and supports 4'-FlU as developmental candidate for the treatment of seasonal and pandemic influenza.
. 2023 Apr 17;19(4):e1011342.
doi: 10.1371/journal.ppat.1011342. Online ahead of print.
4'-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses
Carolin M Lieber[SUP] 1 [/SUP], Megha Aggarwal[SUP] 1 [/SUP], Jeong-Joong Yoon[SUP] 1 [/SUP], Robert M Cox[SUP] 1 [/SUP], Hae-Ji Kang[SUP] 1 [/SUP], Julien Sourimant[SUP] 1 [/SUP], Mart Toots[SUP] 1 [/SUP], Scott K Johnson[SUP] 2 [/SUP], Cheryl A Jones[SUP] 2 [/SUP], Zachary M Sticher[SUP] 3 [/SUP], Alexander A Kolykhalov[SUP] 3 [/SUP], Manohar T Saindane[SUP] 3 [/SUP], Stephen M Tompkins[SUP] 2 [/SUP], Oliver Planz[SUP] 4 [/SUP], George R Painter[SUP] 3 [/SUP], Michael G Natchus[SUP] 3 [/SUP], Kaori Sakamoto[SUP] 5 [/SUP], Richard K Plemper[SUP] 1 [/SUP]
Affiliations
- PMID: 37068076
- DOI: 10.1371/journal.ppat.1011342
Abstract
Influenza outbreaks are associated with substantial morbidity, mortality and economic burden. Next generation antivirals are needed to treat seasonal infections and prepare against zoonotic spillover of avian influenza viruses with pandemic potential. Having previously identified oral efficacy of the nucleoside analog 4'-Fluorouridine (4'-FlU, EIDD-2749) against SARS-CoV-2 and respiratory syncytial virus (RSV), we explored activity of the compound against seasonal and highly pathogenic influenza (HPAI) viruses in cell culture, human airway epithelium (HAE) models, and/or two animal models, ferrets and mice, that assess IAV transmission and lethal viral pneumonia, respectively. 4'-FlU inhibited a panel of relevant influenza A and B viruses with nanomolar to sub-micromolar potency in HAE cells. In vitro polymerase assays revealed immediate chain termination of IAV polymerase after 4'-FlU incorporation, in contrast to delayed chain termination of SARS-CoV-2 and RSV polymerase. Once-daily oral treatment of ferrets with 2 mg/kg 4'-FlU initiated 12 hours after infection rapidly stopped virus shedding and prevented transmission to untreated sentinels. Treatment of mice infected with a lethal inoculum of pandemic A/CA/07/2009 (H1N1)pdm09 (pdmCa09) with 4'-FlU alleviated pneumonia. Three doses mediated complete survival when treatment was initiated up to 60 hours after infection, indicating a broad time window for effective intervention. Therapeutic oral 4'-FlU ensured survival of animals infected with HPAI A/VN/12/2003 (H5N1) and of immunocompromised mice infected with pdmCa09. Recoverees were protected against homologous reinfection. This study defines the mechanistic foundation for high sensitivity of influenza viruses to 4'-FlU and supports 4'-FlU as developmental candidate for the treatment of seasonal and pandemic influenza.